Wegovy, Depression and Anxiety: What Do We Actually Know?

Did regulatory reviews find a link between semaglutide and depression?

In 2023 and 2024, the European Medicines Agency and the MHRA both conducted formal signal reviews of GLP-1 receptor agonists (including semaglutide) after reports of suicidal thoughts and self-harm appeared in pharmacovigilance databases. Both agencies concluded that the available evidence did not establish a causal relationship between these medicines and suicidal ideation or depression. That is an important finding, not a dismissal: signal reviews exist precisely to answer this kind of question rigorously.

The NHS medicines information for semaglutide notes that mood changes should be reported, and the product information lists depression and suicidal thoughts as events to watch for and discuss with a healthcare professional. The fact that something is listed does not mean it is common or confirmed as drug-caused, it means the reporting system is doing its job. You can read the NHS's guidance on semaglutide directly for the full picture.

Ongoing pharmacovigilance continues. That is the right scientific response to an uncertain signal, and it reflects exactly how medicine regulation should work. If you experience low mood or anxiety while taking Wegovy, the relationship between semaglutide and depression is worth understanding in more detail before drawing conclusions about your own experience.

Can Wegovy cause anxiety, and what might explain mood shifts in practice?

Some people do report feeling more anxious after starting Wegovy, and others notice the opposite. The difficulty in interpreting this is that several things change at once when someone begins a weight-loss programme: calorie intake falls, eating patterns shift, GI side effects appear (nausea, bloating, disrupted appetite), and the psychological experience of significant weight change is rarely neutral.

Nausea and discomfort in the first few weeks can produce physiological arousal that feels like anxiety. Low calorie intake, particularly protein, can affect neurotransmitter availability. Sleep can be disturbed. None of these are unique to Wegovy (they are common features of rapid dietary change) but they can make it genuinely hard to separate a drug effect from a lifestyle effect.

For practical detail on how anxiety specifically has been reported in clinical use, this page on Wegovy and anxiety covers the reported frequency and pattern. Separately, anxiety as a Wegovy side effect looks at what the SmPC records and what patients describe. The broader Wegovy side-effects overview sets both mood and GI effects in context against the trial data.

Does the evidence suggest semaglutide helps or harms mental wellbeing overall?

The STEP 1 trial (published in the New England Journal of Medicine) reported improvements in health-related quality of life and physical functioning alongside the 15% average weight loss seen in the semaglutide 2.4mg group. Some participants described lower scores for depression and better emotional wellbeing at 68 weeks compared with baseline. These are secondary and exploratory outcomes rather than primary endpoints, and they reflect averages across a large group, they do not predict any individual's experience.

Weight loss itself has well-documented associations with improved mood in people who have been living with obesity-related health consequences. It is genuinely difficult to disentangle how much of any psychological benefit comes from the medicine's direct action and how much from less joint pain, better sleep, reduced breathlessness and the psychological shift of a body changing in the direction you want.

One thing our prescribers hear fairly often: people who felt nervous before starting treatment (wondering whether semaglutide would make them feel emotionally worse) report that the actual experience was calmer than they expected, once the early GI adjustment settled. Others do not find that. Individual responses vary, which is exactly why a prescriber who knows your history matters. Whether Wegovy can cause anxiety is explored in detail if you want to go deeper on the mechanism.

What should you do if your mood changes after starting Wegovy?

Tell your prescriber. This is not a bureaucratic formality, it shapes clinical decisions. A prescriber can consider whether the timing fits a drug effect, whether a dose adjustment makes sense, whether something else is going on, and whether a pause in treatment is appropriate. Waiting several weeks to mention it is understandable; waiting months is not advisable.

If thoughts of self-harm develop at any point, seek urgent help rather than waiting for a scheduled review. Contact your GP, call 111, or go to A&E. You can also report suspected side effects directly via the MHRA's Yellow Card scheme, patient reports are a genuine part of how the regulatory system monitors emerging signals for medicines like Wegovy.

For mood or anxiety concerns specifically linked to Wegovy, the NHS recommends not stopping treatment abruptly without clinical advice, as that carries its own risks. Our FAQs page covers common queries about managing side effects through treatment. If you are weighing up whether treatment is right for you given a mental health history, that conversation starts at a free consultation with our prescribers, where your full clinical picture is assessed before anything is prescribed. For broader context on how Wegovy works and the cost of treatment, those pages are there if they're useful.